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Abstract
In primary human melanoma, the membrane-type matrix metalloproteinase, MT3-MMP, is overexpressed in the most
aggressive nodular-type tumors. Unlike MT1-MMP and MT2-MMP, which promote cell invasion through basement
membranes and collagen type I-rich tissues, the function of MT3-MMP in tumor progression remains unclear. Here, we
demonstrate that MT3-MMP inhibits MT1-MMP-driven melanoma cell invasion in three-dimensional collagen, while yielding
an altered, yet MT1-MMP-dependent, form of expansive growth behavior that phenocopies the formation of nodular cell
colonies. In melanoma cell lines originating from advanced primary or metastatic lesions, endogenous MT3-MMP expression
was associated with limited collagen-invasive potential. In the cell lines with highest MT3-MMP expression relative to MT1-
MMP, collagen-invasive activity was increased following stable MT3-MMP gene silencing. Consistently, MT3-MMP
overexpression in cells derived from less advanced superficially spreading melanoma lesions, or in the MT3-MMP
knockdown cells, reduced MT1-MMP-dependent collagen invasion. Rather than altering MT1-MMP transcription, MT3-MMP
interacted with MT1-MMP in membrane complexes and reduced its cell surface expression. By contrast, as a potent
fibrinolytic enzyme, MT3-MMP induced efficient invasion of the cells in fibrin, a provisional matrix component frequently
found at tumor-host tissue interfaces and perivascular spaces of melanoma. Since MT3-MMP was significantly upregulated
in biopsies of human melanoma metastases, these results identify MT3-MMP as a matrix-dependent modifier of the invasive
tumor cell functions during melanoma progression.
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Introduction
Cancer-related mortality is generally associated with the
development of metastatic lesions. During the progression to
metastatic cancer, tumor cells invade through extracellular matrix
(ECM) barriers such as the basement membrane and interstitial
stroma, enter vascular or lymphatic vessels, extravasate, and
colonize distant organs [1,2]. Comparisons between the gene
expression profiles of non-metastatic and metastatic cancers have
revealed distinct genetic footprints for each disease state [3]. In
such analyses, the proteolytic enzyme, membrane-type matrix
metalloproteinase 1 (MT1-MMP, MMP14), is often linked to the
metastatic disease [4,5] with the protease upregulated in tumor
cells as well as surrounding stromal cells [6–9]. The strongest
MT1-MMP induction often correlates with the transition of tumor
cells to a rapidly invasive mesenchymal phenotype [10], and its
elevated expression in cancer tissues correlates frequently with
disease aggressiveness and poor prognosis [5,7].
The MT-MMP family comprises six members, MT(1–6)-
MMPs. Each of the proteases have been implicated in tumor
progression, although their expression pattern and known
functions appear distinct [11–14]. MT1- and MT2-MMP
(MMP15) can each drive tumor cell invasion through basement
membranes and the collagen type I-rich interstitial stroma
[10,15], while MT3-MMP (MMP16) cannot efficiently cleave
native collagen type I or confer cells with collagen-invasive ability
in vitro or in vivo [15–17]. However, when overexpressed, both
MT1- and MT3-MMP mediate cell invasion in cross-linked fibrin
gel, a provisional form of extracellular matrix commonly
deposited within tumor tissues and perivascular spaces in vivo
[18]. Unlike wide MT1-MMP expression in different cancers,
notable MT3-MMP mRNA levels have been detected in
relatively few types of cancer, such as gliomas, hepatocellular
carcinoma, gastric cancer and melanoma, where its translation
efficiency, protein expression and function remain poorly defined
[11,19–22].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28325Metastatic melanoma has a poor prognosis with a 5-year
survival rate ranging between 5–10% due to its resistance to
available cancer therapies [23]. As such, understanding the
molecular mechanisms that underlie melanoma metastasis is
essential for the development of new prognostic indicators as well
as strategies for disease treatment. Consistent with the central role
played by MT1-MMP in mediating the pericellular ECM
degradation necessary for cell invasion, the expression of the
protease has been linked to the development of metastatic lesions
in melanoma [4]. Interestingly, MT3-MMP is specifically
upregulated in nodular melanoma, the most aggressive melanoma
type, comprising about 15% of all melanoma cases [24,25]. Unlike
the more common, superficially spreading form of melanoma that
is characterized by a pattern of slow radial growth eventually
followed by vertical growth phase and metastasis, nodular
melanomas grow rapidly in thickness, and are often metastasized
at the time of diagnosis [26]. As the functional contribution of
MT3-MMP in melanoma progression has remained undefined, we
have here examined its function using gene-silencing and
overexpression in different types of melanoma cells. The invasive
and growth properties of these cells were defined within the
confines of the three-dimensional (3D) type I collagen or fibrin
matrices that typify the surrounding host ECM environment.
Results
MT3-MMP is overexpressed in human melanoma
metastases and metastatic melanoma cell lines
MT1-MMP is frequently overexpressed in different types of
melanoma [4,27], whereas mean MT3-MMP expression is not
increased in primary melanoma compared to normal skin
(GeneSapiens, www.genesapiens.org; [28]). However, increased
levels of MT3-MMP are associated with the most aggressive
nodular melanoma [24,25]. To assess if MT3-MMP expression is
more generally linked to melanoma progression, we analyzed
MT1-MMP and MT3-MMP mRNA expression in human tissue
biopsies of normal skin (n=8), benign nevi (n=11), and
melanoma metastases (n=77). Significantly, MT3-MMP was
.8-fold upregulated in the lymph node metastases as compared
to normal skin (p=0.028; Fig. 1A) whereas low MT3-MMP
expression observed in benign nevi was comparable to normal skin
(Fig. 1A). MT3-MMP was also upregulated in melanoma
Figure 1. MT3-MMP is expressed in melanoma lymph node metastases and metastatic cell lines. MT3-MMP (A) and MT1-MMP (B) mRNA
expression levels in human tissue biopsies from normal skin (n=8), nevus (n=11), and melanoma metastases (n=77) were assessed by qPCR. cDNAs
were normalized against beta-actin. Soft tissue comprise metastases obtained from subcutaneous tissue of groin (n=2), pelvis (n=1) and thigh
(n=1). Other organs comprise single or double biopsies from melanoma metastases to skin, stomach, liver, mediastinum, ovary, kidney and brain.
*p=0.028 (p=0.031 if the highest outlying lymph node metastasis value of 84.4 is excluded). (C) Relative values of average MT1-, MT2- and MT3-MMP
mRNA expression were analyzed by qPCR in 7 melanoma cell lines as indicated. (D) The melanoma cells were embedded inside 3D collagen type I
gels. After 4-d culture, the 3D cell/matrix constructs were fixed and stained with TRITC-phalloidin (red) and DAPI (blue). Fluorescence micrographso f
the collagen gels show representative cell colonies.
doi:10.1371/journal.pone.0028325.g001
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single tissue sample of brain metastasis (,4.5-fold). In contrast,
notable MT1-MMP mRNA levels were detected in several of the
normal skin samples, and the slightly increased expression in both
lymph node metastases and benign nevi were not statistically
significant (Fig. 1B).
Furthermore, four different metastatic melanoma cell lines
tested (WM852, WM164, WM165 and WM239) as well as the
Bowes, G361 and WM793 cells derived from non-metastatic
primary melanoma all expressed MT1-MMP, whereas MT3-
MMP was expressed in three cell lines originally isolated from
metastatic melanomas (WM852, WM165 and WM239) and
WM793 cell line isolated from advanced primary melanoma
(Fig. 1C). To investigate the growth and invasion of these cells,
they were implanted as single cells in cross-linked collagen matrix
that typifies the surrounding ECM environment in collagen-rich
skin. Under these conditions, MT1-MMP expression remained
high or was even enhanced as compared to cells in monolayer
culture or inside a 3D fibrin matrix (Fig. S1). Significant MT3-
MMP expression remained unaltered and restricted to the same
cells in the monolayer and 3D cultures (Fig. S1). During a 4-d
culture within collagen, Bowes, G361 and WM164 cells all devoid
of significant MT3-MMP expression grew and invaded efficiently
in elongated morphology (Fig. 1D, upper panel). In contrast, the
MT3-MMP expressing cells grew as either non-invasive sphere-
shaped colonies or groups of rounded cells within collagen (Fig. 1D,
lower panel), suggesting that MT3-MMP could have an effect on
melanoma cell invasion.
MT3-MMP expression is associated with rapid fibrin
invasion and poor collagen invasion
WM852 cells, isolated from the metastatic lesions of nodular
melanoma, and Bowes cells, derived from early stage superficially
spreading melanoma [29–31], were used to begin characterizing
the functions of MT1-MMP and MT3-MMP in melanoma. These
cells expressed MT1-MMP at comparable levels (Fig. 1C and 2A).
By contrast, only WM852 cells expressed significant levels of
MT3-MMP (Fig. 1C and 2A), while neither Bowes nor WM852
cells expressed MT2-MMP (Fig. 1C). To asses the relative invasive
activities of the cells, they were cultured atop 3D gels of type I
collagen, or fibrin, which deposition is enhanced at perivascular
sites as well as tumor-host interfaces of melanoma [32]. During a
7-d culture period, WM852 cells efficiently invaded fibrin gels, but
displayed only minor collagen-invasive activity (Fig. 2B and C). By
contrast, Bowes cells readily invaded both collagen and fibrin
matrices (Fig. 2B and C). In accordance with previously described
functions for MT-MMPs in cell invasion [15,18,33], the ability of
either Bowes or WM852 cells to infiltrate collagen or fibrin gels
was blocked completely by the synthetic MMP-inhibitor, GM6001
(Fig. 2B and C). Taken together, these results suggest that MT3-
MMP expression is compatible with rapid tumor cell invasion into
fibrin, whereas in WM852 cells it was associated with the limited
ability of MT1-MMP to support collagen invasion.
MT3-MMP knockdown enhances WM852 melanoma cell
invasion into collagen
To define the effects of MT3-MMP on the melanoma cell
invasion, we assessed the impact of silencing endogenous MT1-
MMP or MT3-MMP expression by specific siRNAs in WM852
cells (over 80% silencing efficiencies by qPCR; Fig. 3A). The
down-regulation of MT1-MMP or MT3-MMP protein was
confirmed by immunoblotting (Fig. 3B and C). MT3-MMP,
which was detected as the major 65 kDa protein in both control
cells expressing endogenous protease and cells transiently
transfected with MT3-MMP cDNA, was markedly suppressed
by MT3-MMP siRNAs (Fig. 3C). Likewise, endogenous MT3-
MMP detected by surface biotinylation followed by MT3-MMP
immunoprecipitation in control WM852 cells was barely detect-
able after transfection with the most efficient MT3-MMP siRNA
(Fig. 3D). When plated atop the collagen matrices, the control
siRNA-transfected cells displayed only minor invasive potential
during a 5-d assay, which was completely abrogated by MT1-
MMP silencing as expected (Fig. 3E). By contrast, MT3-MMP
knockdown unexpectedly enhanced collagen invasion (1.760.3
fold, n=3, p=0.05), whereas fibrin invasion was inhibited by
silencing either MT1-MMP or MT3-MMP (Fig. 3E).
Figure 2. MT3-MMP expressing WM852 melanoma cells invade
readily fibrin but have limited ability to invade collagen type I.
(A) MT1- and MT3-MMP mRNA expression in WM852 cells from nodular
melanoma and Bowes cells from superficially spreading melanoma
were analyzed by Northern blotting. GAPDH mRNA levels served as an
internal standard. (B) The cells were allowed to invade 3D fibrin and
type I collagen for 7 d. Quantitative results are expressed as the number
of invasive cells per microscopic field (n=3). The number of invasive
cells in fibrin was set to 100%. (C) Light micrographs of fibrin and
collagen cross-sections visualize the invasion of WM852 and Bowes
cells. GM6001 (10 mM) was added where indicated. White dotted lines
mark the surface of the matrix.
doi:10.1371/journal.pone.0028325.g002
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fibrin but restricts collagen invasion
Given the increased collagen-invasive activity of WM852 cells
after MT3-MMP silencing, we next sought to define the effects of
stable MT3-MMP expression on the invasion of Bowes melanoma
cells, which normally display almost undetectable levels of the
transcript. Stable transfectants increased MT3-MMP mRNA
expression ,9-fold (a level ,50% lower than endogenous
expression in WM852 cells) while stimulating fibrin invasion
2.560.3 fold (n=3; p=0.02; Fig. 4A and B). Importantly,
increasing MT3-MMP expression markedly reduced collagen
invasion by ,80% (0.1760.07, n=3; p=0.021; Fig. 4A), thus
shifting the invasive phenotype of Bowes cells towards that
displayed by WM852 cells.
In these stable Bowes cells, MT3-MMP was detected predom-
inantly as a ,37 kDa cleaved fragment by immunoblotting
(Fig. 4C), and GM6001 enhanced the levels of 60–65 kDa
proteins that most likely correspond to the full-length and
activated or differentially glycosylated forms of MT3-MMP
protein (Fig. 4C; [34]). After inhibition of lysosomal degradation
by bafilomycin A, mostly the cleaved 37-35 kDa fragments of
MT3-MMP were increased (Fig. 4C). Nevertheless, the major
MT3-MMP form exposed to biotinylation on the surface of Bowes
cells was the full-length/activated MT3-MMP, whereas only a
faint band corresponding to the 37 kDa fragment was detectable
by surface biotinylation (Fig. 4D). Notably, the cleavage to 37-
35 kDa fragments was inhibited in tandem with dramatically
increased full-length/activated MT3-MMP by simultaneous
treatment with GM6001 and bafilomycin A (Fig. 4C). Since both
GM6001 and the inactivating E247A mutation (MT3E/A, Fig.
S2) that stabilized the 60–65 kDa MT3-MMP also enhanced the
levels of MT3-MMP on the cell surface (Fig. 4D and E), these
results suggest that constitutive autocatalytic processing of the cell
surface MT3-MMP followed by internalization and lysosomal
degradation of the membrane-bound fragments resulted in
unexpectedly rapid MT3-MMP turn-over.
MT3-MMP also slightly reduced the levels of endogenous
MT1-MMP protein in cells cultured on fibrin by ,26%
(0.7460.2), which was reversed by the MMP inhibitor GM6001
(1.1460.2; Fig. 3C). Likewise, MT3-MMP enhanced the cleavage
of MT1-MMP to inactive 37–43 kDa fragments, which were
observed after bafilomycin treatment (1.760.2 -fold increased
processed/total ratio relative to mock; Fig. 4C). Moreover, MT3-
MMP, but not MT3E/A, induced the processing of overexpressed
MT1-MMP mainly to the ,37 kDa fragment after transient co-
transfection (Fig. 4F). This raised the possibility of in trans
processing of the MT-MMPs by a mechanism that would resemble
the autocatalytic cleavages in MT1-MMP homo-dimers or
oligomers [35,36]. Since such processing would require close
physical proximity or interactions, co-immunoprecipitation anal-
yses were carried out. Consistently with an MT1-MMP cleavage
by MT3-MMP, MT1-MMP was co-immunoprecipitated in the
same complexes with MT3-MMP and MT3E/A (Fig. 4F).
However, MT1-MMP expression was less affected by MT3-
MMP in cells cultured on collagen (,20% reduction of 60 kDa
MT1-MMP; 1.460.2 -fold increased processed/total ratio),
suggesting that the regulation of MT1-MMP protein levels may
not be the only mechanism how MT3-MMP alters collagen
invasion.
MT3-MMP reduces cell surface MT1-MMP and functions
as a matrix composition-dependent effector of cell
invasion
To define the interrelated functions of MT1-MMP and MT3-
MMP in cell invasion, COS-1 cells, which are largely devoid of
endogenous MMPs, were engineered to express MT1-MMP,
Figure 3. MT3-MMP silencing inhibits fibrin invasion and enhances collagen invasion of WM852 cells. (A) MT1-MMP and MT3-MMP
mRNA expression in WM852 cells transfected with control siRNA (Ctrl) or siRNAs targeting MT1-MMP (siMT1) or MT3-MMP (siMT3-1 and siMT3-2) were
quantified by qPCR (n=3). (B and C) The protein levels of MT1-MMP (B) and MT3-MMP (C) were assessed by immunoblotting after transient
transfection of the siRNAs or MT3-MMP cDNA (MT3-MMP) as indicated. MT1-MMP was detected as a 60 kDa band and MT3-MMP as 65/60 kDa bands
that were downregulated by the corresponding siRNAs. An additional MT3-MMP fragment of 37 kDa in size was detected in the cells after transient
transfection with MT3-MMP cDNA. Ponceau-staining served as a loading control. Asterix marks a non-specific band. (D) Cell surface MT3-MMP was
detected by surface biotinylation of cells transfected with control siRNA or the most efficient MT3-MMP siRNA (siMT3-1), followed by
immunoprecipitation. Asterix marks a non-specific band. (E) Light micrographs of fibrin and collagen cross-sections visualize the invasion of WM852
cells transfected with the indicated siRNAs. The cells were plated atop 3D fibrin and type I collagen 1 d after siRNA transfections and allowed to
invade for 5 d. Quantitative results are expressed as the number of invasive foci per microscopic field (n=3).
doi:10.1371/journal.pone.0028325.g003
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the fact that both MT1-MMP and MT3-MMP can degrade fibrin
[18], either MT1-MMP or MT3-MMP conferred the cells with
the ability to invade fibrin gels and displayed additive effects when
co-expressed (Fig. 5A). In contrast, while MT1-MMP alone
induced COS-1 cell invasion into collagen matrices, MT3-MMP,
Figure 4. MT3-MMP induces fibrin invasion but inhibits collagen invasion of Bowes melanoma cells. (A) The stable cell pools transfected
with MT3-MMP cDNA (MT3-MMP) or mock vector (Mock) were allowed to invade 3D fibrin or collagen gels for 5 d. Quantitative results are expressed
as the number of invasive cells per microscopic field relative to the mock-transfected cells (n=3, *p=0.02). White dotted lines in the representative
light micrographs of fibrin and collagen cross-sections mark the level below which the invaded cells were counted. (B) Chart shows average MT1-
MMP and MT3-MMP mRNA expression relative to mock-transfected cells as assessed by qPCR. (C) The stable mock or MT3-MMP expressing cells were
treated with GM6001 (10 mM) and bafilomycin A (100 nM) for 16 h as indicated, followed by MT3-MMP and MT1-MMP detection by immunoblotting.
Full-length and processed forms of MT3-MMP were detected as 65/60 kDa and 37 kDa bands, respectively, and MT1-MMP as 60 kDa and 37–43 kDa
bands. Tubulin served as a loading control. Asterix marks a non-specific band. (D) Cell surface MT3-MMP was detected by surface biotinylation of the
stable cells on fibrin and collagen or cells transfected with cDNA for MT3-MMP or catalytically inactive MT3-MMP (MT3E/A) followed by MT3-MMP
immunoprecipitation and detection with peroxidase-conjugated streptavidin. Cells were treated with GM6001 (10 mM) for 16 h prior to surface
biotinylation where indicated. Asterix marks a non-specific band. (E–F) Bowes cells expressing the indicated cDNAs were lysed, followed by
immunoblotting or immunoprecipitation. GM6001 (GM, 10 mM) was added where indicated. Ponceau staining and tubulin served as a loading
control. Asterix marks non-specific bands.
doi:10.1371/journal.pone.0028325.g004
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dependent collagen invasion upon co-expression (Fig. 5A), a result
consistent with the conclusion that MT3-MMP interfered with the
collagen-invasive activity of MT1-MMP in melanoma cells.
In COS-1 cells cultured on either fibrin or collagen the effects of
MT3-MMP co-expression on total MT1-MMP protein levels were
minor (Fig. 5B). In these co-transfected cells, MT1-MMP instead
reduced the levels of full-length MT3-MMP with a concomitant
increase in the processed, 37 kDa fragment of the protease via a
process that was blocked by GM6001 (Fig. 5B). The catalytically-
inactive MT1E/A did not induce MT3-MMP processing (Fig. 5B),
indicating that the increased MT3-MMP cleavage required MT1-
MMP activity. Furthermore, MT3-MMP slightly enhanced the
processing of MT1E/A in the cells cultured on collagen (Fig. 5B).
Figure 5. MT3-MMP regulates cell invasion in a matrix-composition dependent manner by driving fibrin invasion, while reducing
the cell surface levels and collagen invasive activity of MT1-MMP. (A) COS-1 cells transiently transfected to express MT1-MMP (MT1), MT3-
MMP (MT3), or both in combination, were allowed to invade 3D fibrin or collagen gels for 5 d. Quantitative results are expressed as the number of
invasive foci per microscopic field (n=3). (B–C) MT1-MMP, inactive MT1-MMP (MT1E/A), MT3-MMP, and MT3E/A were expressed alone or in different
combinations in COS-1 cells for 48 h followed by immunoblotting and immunoprecipitation as indicated. GM6001 (GM, 10 mM) was added where
indicated. Ponceau-staining and tubulin served as loading controls (n=3). Asterix marks a non-specific band. (D) Cell surface MT1-MMP was detected
from the transfected cells by surface biotinylation followed by immunoprecipitation. Asterix marks a non-specific band. (E) The transfected cells were
fixed and stained for MT1-MMP with an antibody against its catalytic domain. Arrows indicate MT1-MMP staining on the cell surface in the cells
expressing MT1-MMP alone or with inactive MT3E/A, as opposed to the perinuclear staining (arrowheads) in the cells co-expressing MT1-MMP and
MT3-MMP. (F) The transfected cells were embedded in 3D collagen or fibrin as single cell suspension and allowed to grow for 5 d. Relative sizes of
invasive areas per colony were calculated using ImageJ software (n=3). (G) Fluorescence micrographs visualize representative colonies of COS-1 cells
cultured inside collagen or fibrin and stained for filamentous actin.
doi:10.1371/journal.pone.0028325.g005
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and MT3E/A were co-precipitated with MT1-MMP (Fig. 5C).
Interestingly, when 3-fold higher amount of cDNA for MT3-
MMP than for MT1-MMP was transfected, MT1-MMP process-
ing to 37–43 kDa fragments was increased also in COS-1 cells
(Fig. 5C) suggesting that a dose-dependent competition may at
least partially dictate the order of the cleavages between these MT-
MMPs. Furthermore, even after equal transfection of the MT1-
MMP and MT3-MMP cDNAs, MT3-MMP notably enhanced the
processing of the fraction of MT1-MMP and MT1E/A exposed to
cell surface biotinylation (Fig. 5D). Accordingly, MT3-MMP, but
not the catalytically-inactive MT3E/A, decreased cell surface
MT1-MMP in tandem with intracellular MT1-MMP accumula-
tion as detected by immunofluorescence (Fig. 5E and S3).
Since MT1-MMP surface levels can affect 3D growth and
invasion pattern of the cells [37–39], we assessed next the impact
of MT1-MMP and MT3-MMP on 3D cell growth and mode of
invasion. As such, COS-1 cells transiently transfected to express
MT1-MMP, MT3-MMP, catalytically-inactive MT3E/A, or
MT1-MMP and MT3-MMP in combination, were embedded as
single cells in either type I collagen or fibrin gels. During a 5-d
culture period, mock-transfected cells formed small colonies which
were not invasive in either matrix (Fig. 5F and G). As expected,
MT3-MMP-expressing cells invaded only in fibrin (21.666.0 -fold
increase in invasive area compared to mock cells, with a negligible
increase in collagen invasion), whereas MT1-MMP-expressing
cells generated both invasive colonies characterized by multicel-
lular sprouts as well as clusters of cells invading in a single-cell
fashion in either collagen or fibrin gels (in collagen, 9.960.4 –fold
increase in invasive area as compared to mock-transfected cells,
and in fibrin, 17.064.6 –fold increase compared to mock-
transfected cells; Fig. 5F and G). Interestingly, the co-expression
of MT3-MMP with MT1-MMP resulted in weakly sprouting or
sphere-shaped colonies in collagen (Fig. 5F and G), while
increasing fibrin-invasive activity of the cells (28.565.9 –fold
increase compared to mock-transfected cells; Fig. 5F and G). By
contrast, the expression of MT3E/A did not inhibit collagen
invasion or induce fibrin invasion (Fig. 5F and G). These results
indicate that MT3-MMP-dependent proteolytic activity promoted
fibrin invasion, but resulted in decreased MT1-MMP surface levels
and inhibition of collagen invasion.
MT3-MMP enhances fibrin invasion and MT1-MMP-
dependent nodular-type cell growth in 3D collagen
To assess next the impact of the endogenous proteases on
melanoma cell growth and pattern of invasion, WM852 cells were
cultured within 3D collagen gel. The control cells grew as compact
nodular cell colonies, while in 3D fibrin the cells formed invasive
colonies with multicellular sprouts (Fig. 6A and B). As expected,
3D growth in collagen was blocked when MT1-MMP expression
was silenced, a result consistent with previous reports (Fig. 6A;
[37]). Remarkably, following MT3-MMP knockdown by siRNAs
or by lentiviral shRNAs (Fig. S4A), the cell colonies in collagen
became irregular in outline and displayed invasive activity, while
the average size of the colonies was less affected (Fig. 6A and B,
Fig. S4B). Concomitantly with increased collagen invasion, MT1-
MMP levels on the cell surface were increased after MT3-MMP
knockdown, as assessed by surface biotinylation and immunoflu-
orescence (6C and D), while MT1-MMP mRNA remained
unaffected (Fig. S4A). In contrast, efficient MT3-MMP silencing
by shMT3-1 and shMT3-2 significantly reduced both colony size
and invasive sprout formation in 3D fibrin (Fig. 6A and B). These
changes correlated with the dose of MT3-MMP, as the modest
MT3-MMP knockdown by shMT3-3 had only minor effects on
the matrix composition dependent 3D growth and invasion
(Fig. 6B and S4A). Likewise, stable MT3-MMP knockdown in
the MT3-MMP expressing WM165 melanoma cells (Fig. S4C) led
to increased cell elongation and invasive sprouting of cell colonies
in collagen (Fig. 6B and S4D). Unexpectedly, MT3-MMP
knockdown reduced the invasion of WM852 cells in fibrin even
more efficiently than MT1-MMP knockdown (Fig. 6A; relative
colony size 0.6060.04, and invasion 0.4160.1 for siMT1-MMP
transfected cells; size 0.4660.04, and invasion 0.2060.02 for
siMT3-MMP transfected cells, n=3). MT3-MMP silencing also
dramatically reduced the invasive growth of WM165 cell colonies
in fibrin (Fig. 6B and S4D). In contrast, the invasion and growth of
WM793 cells with higher MT1-MMP to MT3-MMP expression
ratio was only slightly affected in 3D collagen by MT3-MMP
knockdown (Fig. 1, S4E and S4F). The MT3-MMP knockdown
also did not alter growth or invasion of Bowes cells in 3D collagen
or fibrin, consistent with the low expression levels of endogenous
MT3-MMP in these cells (Fig. S5A–D).
To confirm the specific invasion regulating functions of MT3-
MMP in collagen and fibrin matrices, we constructed two MT3-
MMP rescue plasmids with silent mutations in the shMT3-2
targeting sequence (rescMT3-1 and rescMT3-2; Fig. 7A). Tran-
sient transfection of these constructs in the MT3-MMP knock-
down WM852 cells diminished collagen invasion and facilitated
fibrin invasion (over 70% transfection efficiency in the shMT3-2
cells using TransIT-2020), indicating that the observed 3D cell
phenotypes were indeed MT3-MMP-dependent (Fig. 7B and C).
Likewise, the enhanced collagen invasion of the MT3-MMP
knockdown cells was reversed to the level seen in scrambled
shRNA expressing cells after transient expression of the rescue
constructs in the knockdown cells (Fig. 7D). Taken together, these
results suggest that MT3-MMP, essential for WM852 and WM165
melanoma cell invasion in fibrin, is a strong negative regulator of
melanoma cell invasion within 3D collagen, where it induced
adhesive nodular-type growth pattern.
Discussion
Unlike the strongly pro-invasive MT1-MMP that is widely
overexpressed in the aggressive and metastatic tumors, MT3-
MMP expression has been reported in only a few tumor types
[11,19–21]. These include nodular melanoma, the most aggressive
melanoma subtype characterized to date [24,25]. Consistent with
the compact sphere-like growth pattern characteristic for nodular
melanoma, we found that WM852 cells, originally derived from a
nodular melanoma metastasis, and the other MT3-MMP
expressing cell lines from advanced melanomas grew within 3D
type I collagen gels as nodular-type adhesive cell colonies. These
colonies displayed a limited ability for invasion of the surrounding
collagen matrix as single cells or multicellular sprouts. Unexpect-
edly, this cell phenotype was dependent on MT3-MMP as
silencing its expression enhanced MT1-MMP-driven collagen
invasion. Since the nodular-type growth phenotype was rescued
when MT3-MMP was overexpressed in the knockdown cells,
MT3-MMP is not only unable to support type I collagen-invasive
activity [16,17], but also restricts the proinvasive activity of MT1-
MMP in our 3D experimental model. By contrast, MT3-MMP –
both alone and in combination with MT1-MMP – conferred cells
with prominent fibrin-invasive activity.
In addition to invasion, MT1-MMP is required for tumor
growth within the confines of cross-linked matrices of type I
collagen, a hydrogel whose structural and mechanical character-
istics mimic those of most interstitial tissues in vivo [33,37]. The
pattern of tumor cell growth in collagen can occur either invasively
MT3-MMP in Matrix-Dependent Melanoma Invasion
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MT1-MMP surface levels and activity [38]. In contrast,
recombinant MT3-MMP is a poor type I collagenase [16] and
unable to drive cell invasion through native polymerized collagen
type I matrix [17,33], although MT3-MMP itself has also been
implicated in the remodeling of 3D collagen [40,41]. In our
experiments, Bowes cells derived from superficially spreading
melanoma invaded rapidly in 3D collagen as single cells as well as
multicellular sprouts in an MT1-MMP dependent manner. As
such, MT1-MMP activity could support both local superficial
spreading in epidermal and upper dermal tissues as well as
invasion into deeper portion of the dermis. However, the collagen-
invasive phenotype of Bowes cells was reduced following co-
expression of catalytically-active MT3-MMP. These observations
are not confined to melanoma cells as COS-1 cells expressing
MT1-MMP alone were also highly invasive in 3D collagen, while
cells expressing both MT1- and MT3-MMP exhibited only limited
collagen invasive ability. By restricting single cell invasion and
sprouting, MT3-MMP co-expression led to the MT1-MMP-
dependent expansion of nodular cells colonies in 3D collagen.
Given the inability of MT3-MMP to degrade native collagen
type I directly and the importance of MT1-MMP homodimeriza-
tion for its activity in collagen degradation [42], we considered the
possibility that MT1-MMP/MT3-MMP heterodimers might form
a complex that fails to support collagen adhesion or unwinding.
However, although both catalytically active and inactive MT3-
MMPs co-immunoprecipitated with MT1-MMP, the catalytically-
inactive MT3-MMP mutant did not suppress MT1-MMP-
mediated collagen invasion. Alternatively, MT3-MMP could
suppress collagen invasion by cleaving MT1-MMP to inactive
fragments, or indirectly by catalyzing the processing of other co-
operative or invasion regulating proteins such as cell surface
Figure 6. MT3-MMP promotes invasion in 3D fibrin and adhesive, nodular-type cell growth in 3D collagen. (A) WM852 cells transfected
with the siRNAs against MT1-MMP (siMT1-MMP) and MT3-MMP (siMT3-MMP) were embedded in 3D collagen type I or fibrin gels as single cell
suspension. Light micrographs show representative cell colonies that were formed after 5-d assay. Chart on the right shows the relative sizes of the
cell colonies (n=3). (B) Stable WM852 and WM165 cell pools expressing control scrambled shRNA (scr) or MT3-MMP targeting shRNAs (shMT3-1,
shMT3-2 and shMT3-3) were allowed to grow inside 3D collagen or fibrin gels for 14 d. The fixed 3D cultures were stained with TRITC-phalloidin and
photographed (see Fig. S4D for representative micrographs of WM165 cell colonies). Chart shows relative areas of invasive sprouts. (C) Cell surface
MT1-MMP and MT3-MMP were detected by surface biotinylation of stable WM852 cells expressing the most potent shRNA against MT3-MMP (shMT3-
2) or scrambled shRNA (Scr), followed by immunoprecipitation using MT1-MMP and MT3-MMP antibodies. WM852 cells after transient transfection
with MT3-MMP cDNA (MT3-MMP) were used as a control for the immunoprecipitation of endogenous MT3-MMP. (D) Epifluorescence micrographs
visualize the increased MT1-MMP (green) on the surface of shMT3-2 expressing cells. The cells were counterstained with DAPI for nuclei (blue) and
phalloidin for filamentous actin (red).
doi:10.1371/journal.pone.0028325.g006
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and Bowes cells, MT3-MMP overexpression decreased cell surface
MT1-MMP concomitantly with increased MT1-MMP processing
to the inactive fragments. In contrast, such processing of
endogenous MT1-MMP or MT3-MMP was less evident in
WM852 cells, which could be at least partially due to the higher
expression levels of TIMP2 and TIMP3 that could inhibit and thus
stabilize the MT-MMPs in these cells [29]. However, MT1-MMP
levels were increased also on the WM852 melanoma cell surface
after knockdown of endogenous MT3-MMP. Thus, the reduced
MT1-MMP surface localization was a consistent property of the
growing, but modestly invasive cell phenotype induced by MT3-
MMP in 3D collagen.
Stabilized intratumoral fibrin networks have been implicated in
the progression of several human neoplasms, including brain
tumors that are almost devoid of type I collagen [45,46]. Since
MT3-MMP expression is upregulated frequently in tumors that
arise in collagen-poor tissues ([28,47]; www.oncomine.org; www.
genesapiens.org), and the effects of MT1-MMP and MT3-MMP
were additive promoting invasion in fibrin, MT3-MMP expression
in primary tumors associated with fibrin accumulation may
promote local tumor spread. This hypothesis and the importance
of MT3-MMP for fibrin invasion is strongly supported by our
finding that silencing endogenous MT3-MMP in two different
melanoma cell lines reduced dramatically their ability to invade
and form sprouts in 3D fibrin. Although melanoma arises in
collagen-rich skin, abundant fibrin accumulation is frequently
found in these tumors within perivascular spaces as well as the
vascular and lymphatic vessel-rich tumor-host tissue interface [32].
Within these fibrin-rich sites, MT3-MMP-dependent proteolysis
could enhance the passage of melanoma cells into lymphatic
vessels, where discontinued basement membranes do not form
significant barriers for cell invasion [48,49].
In addition to primary tumor sites, the accumulation of fibrin-
rich provisional matrices around the circulating melanoma cell
embolus promotes their metastatic capacity in lungs and lymph
nodes [50,51]. As such, MT3-MMP could further accelerate the
metastatic process in such environments via its ability to affect
pericellular fibrin remodeling. Consistent with these proposed pro-
metastatic functions, MT3-MMP expression was increased in
biopsies of human melanoma metastasis. While the nodular vs.
superficially spreading origin of the biopsied tissues of the
metastatic lesions had not been defined, MT3-MMP expression
was not restricted to nodular melanoma-derived cell lines. Rather,
WM165 and WM239 cells derived from the metastases of
superficially spreading melanoma as well as in WM793 cells
isolated from vertical growth phase primary melanoma also
expressed the protease. In this regard, it is interesting to note that
the formation of metastatic foci may also depend on the ability of
tumor cells to form adhesive expansively growing colonies [52].
Since MT3-MMP had similar effects in the invasive activities of
WM852 cells from nodular melanoma metastases and WM165
cells originated from superficially spreading melanoma metastases,
we postulate that the protease may play previously unappreciated
role in the metastatic process.
To date, minimal information is available about any functions
of endogenous MT3-MMP in tumor cells, and the relevant ECM
and non-ECM substrates for MT3-MMP remain poorly defined.
As supported by a recent report of Nogo receptor 1 shedding by
endogenous MT3-MMP in neurons [53], MT3-MMP may
modulate also melanoma cell invasion by cleaving transmembrane
or pericellular proteins. Like MT1-MMP, MT3-MMP is also
efficient cell surface activator of proMMP2 [21]. However, MMP2
is inefficient in driving cell invasion in collagen or fibrin alone
[15,18]. In addition, current results revealed opposing effects of
MT3-MMP on fibrin, that is its own substrate, and on collagen
type I, that is a poor substrate for MT3-MMP but is instead
efficiently cleaved by MT1-MMP. Since MT3-MMP concomi-
tantly reduced MT1-MMP from the surface and MT1-MMP-
dependent collagen invasion, current results suggest that MT3-
MMP restricts the proinvasive MT1-MMP activity and cell
invasion in type I collagen-rich tissues, thus promoting the
expansion of nodular melanoma cell colonies. However, as
endogenous MT3-MMP activity remains unaffected by MT1-
MMP, its fibrinolytic potential could provide melanoma cells with
Figure 7. Transient MT3-MMP expression in the MT3-MMP
knockdown cells rescues nodular-type growth in collagen in
conjunction with increased fibrin invasion. (A) MT3-MMP was
detected by immunoblotting in COS-1 cells transiently expressing mock
vector (Mock), MT3-MMP (MT3), or rescue constructs rescMT3-1 and
rescMT3-2. Ponceau staining served as a loading control. Asterix marks
non-specific bands. (B) WM852 cells stably expressing MT3-MMP
targeting shRNA (shMT3-2) transfected to express MT3-MMP rescue
vectors (rescMT3-1 and rescMT3-2) or mock vector were embedded in
3D collagen type I and fibrin gels. Chart shows relative percentage of
invasive colonies formed after 5 d, n=3. (C) Fluorescent micrographs
show representative colonies stained for F-actin (red) to visualize the
cells. (D) WM852 cell pools after lentiviral expression of scrambled
shRNA (Scr) and shMT3-2 as well as knockdown cells transfected with
MT3-MMP rescue vectors (rescMT3-1 and rescMT3-2) were allowed to
invade into collagen type I gels for 7 d followed by imaging and
quantification, n=3.
doi:10.1371/journal.pone.0028325.g007
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cell surrounding provisional matrices during melanoma progres-
sion.
Materials and Methods
Antibodies and reagents
The following antibodies were used: rabbit polyclonal antibod-
ies against MT1-MMP cytoplasmic tail [35] or hinge domain
(RP1, Triple Point Biologics; Ab6004, Chemicon), mouse
monoclonal antibodies against MT1-MMP catalytic domain
(LEM2-15/8; Millipore) and hemagglutinin (HA; Covance).
Rabbit polyclonal antibodies against MT3-MMP hinge domain
were from Abcam (ab38968), or kindly provided by Dr. R.
Fridman (Wayne State University, Detroit, USA; Ab318). The
MMP inhibitor, GM6001 (Calbiochem), phalloidin-TRITC,
collagen type I from rat tail (Sigma-Aldrich), bafilomycin A1
(Calbiochem) and recombinant human HGF (R&D systems) were
also used.
Cell culture
Human Bowes melanoma cell line, derived from radial growth
phase superficially spreading melanoma [30], was obtained from
Dr D. B. Rifkin (Rockefeller University, New York, USA). The
other human melanoma cell lines used have been established at
the Wistar Institute (Philadephia, PA; [29]). They were originally
derived from primary superficially spreading melanoma (G361
and WM793), nodular melanoma metastases (WM852 and
WM164), or metastasis of superficially spreading melanoma
(WM165 and WM239; [31,54,55]). Melanoma cells were
cultivated in Eagle’s Minimal Essential Medium (MEM) contain-
ing 10% heat-inactivated fetal calf serum (FCS). COS-1 monkey
kidney cells were cultured according to the instructions (American
Type Culture Collection). To generate stable cell pools, transfect-
ed Bowes cells were selected using G418 (400 mg/ml; Calbio-
chem).
RNA isolation from human tissues and cultured cells
Total mRNAs were extracted from representative microdissect-
ed samples of archival paraffin-embedded biopsies of benign
intradermal or compound melanocytic nevi (n=11) and of
adjacent normal skin (n=2) using High Pure RNA Paraffin Kit
(Roche) or from cultured cells using RNeasy Mini kit (Qiagen).
The nevus biopsies had been removed for diagnostic purposes and
the histological diagnosis had been confirmed by the university
hospital dermatopathologist. For RNA isolation from 3D cultures,
collagen and fibrin were first digested using collagenase type 2
(Worthington) and trypsin (Sigma-Aldrich), respectively (both
2 mg/ml). The cells were then collected by brief centrifugation
and lysed for RNA isolation using the RNeasy Mini kit. Reverse
transcription was carried out with Random hexamer primers
(Invitrogen) and Superscript III reverse transcriptase (Life
Technologies). In addition, TissueScan Melanoma Tissue qPCR
Arrays I and II (OriGene Technologies) containing cDNAs from
human tissue biopsies of normal skin (n=6) and melanoma
metastases (n=77) were used for the quantification of the MT-
MMP transcripts.
qPCR
The cDNAs were amplified on GeneAmp 7500 Sequence
Detector thermal cycler (Applied Biosystems) using TaqMan
Universal PCR Master Mix and validated primers (MT1-MMP;
Hs 01037006_gH, MT2-MMP; Hs 00233997_m1, MT3-MMP;
Hs 00234676_m1, Applied Biosystems). The expression levels
were normalized with mRNA for TATA-binding protein (TBP).
Cell invasion and growth in collagen
Cell invasion was assessed essentially as described [33,56].
Briefly, type I collagen (4.8 mg/ml, rat tail) was mixed with equal
amount of 26MEM, and pH was adjusted to ,7.4 by NaOH.
Collagen was cast in the upper chambers of Falcon cell culture
inserts in 24 well plates and incubated at 37uC for 1 h to allow
gelling. Cross-linked fibrin gels were cast in the inserts by
combining 75 ml plasminogen-free human fibrinogen (6 mg/ml;
Calbiochem) in Hank’s Balanced Salt Solution (HBSS) and 75 ml
HBSS (pH 7.4) containing 4 U/ml human thrombin and 400 mg/
ml aprotinin (both from Sigma-Aldrich). Cells were seeded atop
the matrix in the upper chamber in medium containing 1% FCS.
GM6001 (10 mM) was added to both upper and lower chambers
when used. HGF (25 ng/ml) and medium containing 10% FCS
served as chemoattractants in the lower chambers, with medium
changed every third day. After a 5–7 d culture period, the cells
were fixed with 4% PFA, and paraffin sections were stained with
hematoxylin and eosin (H&E-staining). Sections were photo-
graphed, and the invaded cells were counted from 8 random
sections of each sample. Each assay was performed in triplicate.
For 3D growth/invasion assays, collagen (2.4 mg/ml) and fibrin
were prepared as above. 5000 cells were suspended in 40 ml
hydrogel, the suspension were transferred to a 24-well plate, and
incubated for 1 h at 37uC to allow complete gelling. After 4–16 d
incubation in complete growth medium, cultures were fixed and
photographed using Axiovert 200 microscope (Carl Zeiss).
Alternatively, collagen or fibrin gels were stained with phalloi-
din-TRITC to visualize filamentous actin, and photographed
using Axioplan upright epifluorescence microscope (Carl Zeiss).
The invasive areas were calculated from 20 random phase-
contrast or epifluorescence images of 6 separate gels (49–163
colonies/transfected cell line, n=3) using ImageJ software.
Northern hybridization
Total cellular RNA (10 mg) was fractioned by formaldehyde-
agarose gel electrophoresis and transferred to a Zeta probe
membrane (Bio-Rad) in 206 SSC (16 SSC: 150 mM NaCl,
15 mM sodium citrate, pH 7.0) and fixed by UV crosslinking.
cDNA probes corresponding to full-length MT1-MMP and MT3-
MMP cDNA were labeled with [
32P] dCTP by the random
priming method (Amersham Pharmacia Biotech). The membranes
were hybridized in ExpressHyb hybridization solution (Clonetech)
at 58uC for 16–24 h. Washing was carried out in 0.26 SSC
containing 0.1% SDS at 63uC. RNA for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal
standard.
RNA interference and cDNAs
Small interfering RNAs (siRNA) targeting MT1-MMP
(59CAGCGATGAAGTCTTCACTTA93 and 59TGGCGGGT-
GAGGAATAACCAA93), MT3-MMP (59CCGCCACATACTG-
TACTGTAA93 and 59AAGCACATCACTTACAGTATA93) and
non-silencing control siRNAs (Qiagen) were transfected using
Lipofectamine
TM 2000 (Life Technologies). Short hairpin RNA
(shRNA) targeting MT3-MMP (shMT3-1, TRCN0000052249;
shMT3-2, TRCN0000052250; and shMT3-3, TRCN0000052251)
or nontargeting scrambled shRNA (Open Biosystems) in pLKO.1
vector were delivered into the cells using lentiviral transduction as
described [57]. For stable shRNA expression cells were selected
using puromycin (5 mg/ml). The knockdown efficiency was assessed
by quantitative PCR (qPCR) after 48 h. Expression vectors for
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point mutation (MT1E/A) and HA-tagged MT1-MMP have been
described [17,18,58] and were transfected using FuGENE (Roche)
or TransIT-2020 (Mirus). Inactive MT3-MMP E247A construct
(MT3E/A) was kindly provided by Dr. D. Pei [34]. Rescue
constructs for MT3-MMP with double silent mutations in shMT3-2
binding sequence rescMT3-1 (T822C-T825C) and rescMT3-2
(T831C-A836C) were generated with primers (59CTACAGT-
GAATTAGAAAATGGCAAACGCGACGTGGATATAACC93
and 59GGTTATATCCACGTCGCGTTTGCCATTTTCTAA-
TTCACTGTAT93) and (59GGCAAACGTGATGTGGACAT-
CACCATTATTTTTGCATCTGG93a n d5 9CCAGATGCAAA-
AATAATGGTGATGTCCACATCACGTTTGCC93), respec-
tively, using QuikChangeH Site-Directed Mutagenesis Kit (Strata-
gene).
Immunoblotting
Cells were lysed with RIPA buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% NP-40, 0.5% NaDOC, 0.1% SDS)
containing CompleteH protease inhibitor cocktail (Roche).
Protein contents of the lysates were determined by bicinchoninic
acid protein assay (Sigma-Aldrich). Equivalent quantities of
protein were size-fractionated by gradient (4–20%) SDS-PAGE
followed by transfer to polyvinylidene difluoride membranes. The
non-specific protein binding sites were saturated with 5% non-fat
milk in TTBS-buffer (TBS containing 0.05% Tween-20) for
30 min. The membranes were washed with TTBS and incubated
with primary antibodies overnight, and with biotinylated
secondary antibodies (Dako) for 30 min. After incubation with
horseradish peroxidase –conjugated streptavidin for 20 min (GE
Healthcare), the bound antibodies were detected using enhanced
chemiluminescence (Promega). All experiments were repeated for
2–4 times.
Immunoprecipitation
Endogenous or recombinant MT1-MMP and MT3-MMP were
immunoprecipitated from cell lysates by incubation with specific
rabbit polyclonal antibodies for MT3-MMP (against hinge
domain; Ab38968) or MT1-MMP (against cytoplasmic tail [35]
or hinge region; AB6004, Chemicon) and G protein sepharose
(GE Healthcare) for 2 h at 4uC. The sepharose particles were then
pelleted by centrifugation and washed extensively with PBS. The
proteins were eluted with the sample buffer and separated for
immunodetection by SDS-PAGE.
Cell surface labeling
Cell surface biotinylation was performed as described [35].
Briefly, cells were rinsed twice with PBS and incubated with
0.5 mg/ml biotin (Pierce) in PBS on ice for 1 h. The reaction was
terminated by washing 3 times for 10 min with 150 mM glycine/
TBS. The cells were then lysed and subjected to immunoprecip-
itation with rabbit polyclonal MT1-MMP or MT3-MMP
antibodies. The immunoprecipitated material was resolved by
SDS-PAGE, and detected with horseradish-peroxidase-conjugated
streptavidin (Daco).
Immunofluorescence
The cells on glass coverslips were fixed with 4% PFA followed
by staining with the indicated primary antibodies and Alexa Fluor-
labeled secondary antibodies (Invitrogen). The coverslips were
finally mounted on glass slides using Vectashield anti-fading
reagent (Vector Laboratories) and examined using the Axioplan
microscope.
Gelatin zymography
MMP-2 was transiently expressed in COS-1 cells, and the
conditioned medium was harvested after 18 h. Aliquots of the
conditioned medium were incubated with COS-1 cells overex-
pressing MT1- and MT3-MMPs for 24 h. Aliquots of conditioned
medium were then subjected to the gelatin zymography [57].
Statistical analysis
All numerical values represent mean 6 SD. Statistical
significance was determined using the Mann-Whitney test.
Supporting Information
Figure S1 MT1-MMP and MT3-MMP expression in
melanoma cells cultured within 3D collagen and fibrin.
Relative values of average MT1-MMP (A) and MT3-MMP (B)
mRNA expression in indicated melanoma cell lines cultured inside
3D collagen and fibrin gels for 48 h were analyzed by qPCR.
MT1-MMP and MT3-MMP mRNA expression in Bowes cells
cultured in collagen were set to 100%, n=3.
(TIF)
Figure S2 Catalytically inactive MT3-MMP does not
activate MMP-2. Gelatin zymogram shows MT1-MMP-medi-
ated MMP-2 activation by COS-1 cells expressing MT1-MMP,
MT3-MMP or MT3E/A. MMP-2: latent (L), intermediate (I) and
active (A). After harvesting of conditioned media, the cell lysates
were subjected to immunoblotting for MT3-MMP and MT1-
MMP.
(TIF)
Figure S3 MT3-MMP reduces MT1-MMP on the cell
surface. COS-1 cells transiently expressing MT1-MMP or MT1-
MMP in combination with MT3-MMP or MT3E/A were fixed
and stained with antibodies against the hinge domain (RP1) and
catalytic domain (LEM2-15/8) of MT1-MMP. Magnified areas
indicated by white boxes are presented below the each image for
RP1 staining, and on figure 5E for LEM2-15/8 staining.
(TIF)
Figure S4 MT3-MMP modulates collagen and fibrin
invasion of three different melanoma cell lines. (A)
Average MT1-MMP and MT3-MMP mRNA expression in the
WM852 cell pools expressing shRNA against MT3-MMP
(shMT3-1, shMT3-2 and shMT3-3) relative to cells expressing
scrambled shRNA (Scr). (B) WM852 cells stably expressing
indicated shRNAs were embedded in 3D collagen type I or fibrin
gels as single cell suspension. Light micrographs show represen-
tative cell colonies that were formed after 7-d assay. (C) Average
MT-MMP mRNA expression in the WM165 cells expressing
indicated shRNAs. (D) WM165 cells expressing indicated shRNAs
were cultured inside 3D collagen type I and fibrin for 14 d, after
which cultures were fixed and stained for filamentous actin.
Quantifications of invasive areas are presented on figure 6B. (E)
Average MT-MMP mRNA expression in the WM793 cells stably
expressing indicated shRNAs. (F) Light micrographs show
representative WM793 cell colonies that were formed in 3D
collagen and fibrin after 16-d assay.
(TIF)
Figure S5 Silencing of MT3-MMP does not have any
notable effect on Bowes cell invasion. (A) MT1-MMP and
MT3-MMP mRNA levels in Bowes cells transfected with control
siRNA (Ctrl) or siRNAs targeting MT1-MMP (siMT1) or MT3-
MMP (siMT3) were detected by qPCR (n=3). (B) Cells
transfected with the indicated siRNAs were allowed to invade
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expressed as the number of invasive foci per microscopic field
(n=3). (C) Light micrographs of fibrin and collagen cross-sections
visualize the invasion of Bowes cells transfected with the indicated
siRNAs. White dotted lines mark the surface of the matrix. (D)
Cells transfected with the indicated siRNAs were embedded in 3D
collagen type I gels as single cell suspension. Light micrographs
show the cells after 5-d assay (n=3).
(TIF)
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